Lanreotide reduces serum free and total insulin-like growth factor-I after angioplasty.

Frystyk J, Skjaerbaek C, Alexander N, Emanuelsson H, Suryapranata H, Beyer H, Foegh M, Orskov H

Circulation1 Nov 1996Cited by 12 (Europe PMC)

PMID8921789DOI10.1161/01.cir.94.10.2465PepBankPUB-08921789

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients undergoing PTCA in a controlled trial, total IGF-I fell by 7% from baseline 1 day after lanreotide infusion started (P < .0001) and stayed reduced, with no early change in placebo-treated patients.
In plain wordsIn patients having angioplasty, total IGF-I was lower one day after lanreotide infusion began and stayed lower, with no early change on placebo.
Peptide
Lanreotide
Outcome
DecreaseTotal IGF-I
Study
n = 553
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · continuous subcutaneous infusion · from the day before PTCA through 4 days after PTCAAs given in this study (human).
Measurements
Change in total IGF-I
7 % decrease
lanreotide group, 1 day after infusion start
Source sentences
Summary
Total IGF-I had decreased by 7% (P < .0001) 1 day after initiation of lanreotide infusion and stayed reduced, whereas no early changes occurred in placebo-treated patients.
3 context sentences(design, population, supporting numbers)
Summary · context
We measured fasting serum total (extractable) IGF-I in 553 patients in a controlled clinical trial.
Summary · context
Half of the patients received continuous subcutaneous infusion of the somatostatin analogue lanreotide from the day before (baseline) and for 4 days after PTCA.
Summary · context
We also measured ultrafiltrated serum free IGF-I and IGF-II, total IGF-II, IGF-binding protein-1 (IGFBP-1), IGFBP-3, and insulin in a subgroup of 18 placebo-treated and 20 lanreotide-treated patients.
Report a problemFND-0892178901
02HumanNon-randomized trialEfficacy outcome
In PTCA patients, free IGF-I fell 22%-27% from baseline with lanreotide (P < .05), versus an insignificant 10%-30% increase with placebo (P = .054).
In plain wordsIn PTCA patients, free IGF-I decreased from baseline with lanreotide but increased without statistical significance with placebo.
Peptide
Lanreotide
Outcome
DecreaseFree IGF-I
Study
n = 38
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · continuous subcutaneous infusion · from the day before PTCA through 4 days after PTCAAs given in this study (human).
Measurements
Change in free IGF-I from baseline
22 to 27 % decrease
lanreotide-treated patients
Change in free IGF-I from baseline
10 to 30 % increase
placebo-treated patients (insignificant)
Source sentences
Summary
Free IGF-I decreased significantly from baseline by 22% to 27% (P < .05) in lanreotide-treated patients and increased insignificantly by 10% to 30% (P = .054) in placebo-treated patients.
3 context sentences(design, population, supporting numbers)
Summary · context
We measured fasting serum total (extractable) IGF-I in 553 patients in a controlled clinical trial.
Summary · context
Half of the patients received continuous subcutaneous infusion of the somatostatin analogue lanreotide from the day before (baseline) and for 4 days after PTCA.
Summary · context
We also measured ultrafiltrated serum free IGF-I and IGF-II, total IGF-II, IGF-binding protein-1 (IGFBP-1), IGFBP-3, and insulin in a subgroup of 18 placebo-treated and 20 lanreotide-treated patients.
Report a problemFND-0892178902
03HumanNon-randomized trialEfficacy outcome
After PTCA, IGFBP-1 increased in both groups, but levels were higher with lanreotide than placebo (P < .05).
In plain wordsAfter PTCA, IGFBP-1 increased in both groups but was higher with lanreotide than placebo.
Peptide
Lanreotide
Outcome
IncreaseIGFBP-1
Study
n = 38
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · continuous subcutaneous infusion · from the day before PTCA through 4 days after PTCAAs given in this study (human).
Source sentences
Summary
IGFBP-1 increased (P < .05) in both groups postoperatively, but levels in lanreotide-treated patients exceeded (P < .05) those of placebo-treated patients.
3 context sentences(design, population, supporting numbers)
Summary · context
We measured fasting serum total (extractable) IGF-I in 553 patients in a controlled clinical trial.
Summary · context
Half of the patients received continuous subcutaneous infusion of the somatostatin analogue lanreotide from the day before (baseline) and for 4 days after PTCA.
Summary · context
We also measured ultrafiltrated serum free IGF-I and IGF-II, total IGF-II, IGF-binding protein-1 (IGFBP-1), IGFBP-3, and insulin in a subgroup of 18 placebo-treated and 20 lanreotide-treated patients.
Report a problemFND-0892178903
04HumanNon-randomized trialEfficacy outcome
In PTCA patients, lanreotide produced a minor reduction in free IGF-II (P < .05).
In plain wordsIn patients undergoing PTCA, lanreotide reduced free IGF-II.
Peptide
Lanreotide
Outcome
DecreaseFree IGF-II
Study
n = 20
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · continuous subcutaneous infusion · from the day before PTCA through 4 days after PTCAAs given in this study (human).
Source sentences
Summary
Lanreotide treatment resulted in minor reductions (P < .05) in free and total IGF-II and IGFBP-3, whereas insulin was unaltered.
3 context sentences(design, population, supporting numbers)
Summary · context
We measured fasting serum total (extractable) IGF-I in 553 patients in a controlled clinical trial.
Summary · context
Half of the patients received continuous subcutaneous infusion of the somatostatin analogue lanreotide from the day before (baseline) and for 4 days after PTCA.
Summary · context
We also measured ultrafiltrated serum free IGF-I and IGF-II, total IGF-II, IGF-binding protein-1 (IGFBP-1), IGFBP-3, and insulin in a subgroup of 18 placebo-treated and 20 lanreotide-treated patients.
Report a problemFND-0892178904
05HumanNon-randomized trialEfficacy outcome
In PTCA patients, lanreotide produced a minor reduction in total IGF-II (P < .05).
In plain wordsIn patients undergoing PTCA, lanreotide reduced total IGF-II.
Peptide
Lanreotide
Outcome
DecreaseTotal IGF-II
Study
n = 20
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · continuous subcutaneous infusion · from the day before PTCA through 4 days after PTCAAs given in this study (human).
Source sentences
Summary
Lanreotide treatment resulted in minor reductions (P < .05) in free and total IGF-II and IGFBP-3, whereas insulin was unaltered.
3 context sentences(design, population, supporting numbers)
Summary · context
We measured fasting serum total (extractable) IGF-I in 553 patients in a controlled clinical trial.
Summary · context
Half of the patients received continuous subcutaneous infusion of the somatostatin analogue lanreotide from the day before (baseline) and for 4 days after PTCA.
Summary · context
We also measured ultrafiltrated serum free IGF-I and IGF-II, total IGF-II, IGF-binding protein-1 (IGFBP-1), IGFBP-3, and insulin in a subgroup of 18 placebo-treated and 20 lanreotide-treated patients.
Report a problemFND-0892178905
06HumanNon-randomized trialEfficacy outcome
In PTCA patients, lanreotide produced a minor reduction in IGFBP-3 (P < .05).
In plain wordsIn patients undergoing PTCA, lanreotide reduced IGFBP-3.
Peptide
Lanreotide
Outcome
DecreaseIGFBP-3
Study
n = 20
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · continuous subcutaneous infusion · from the day before PTCA through 4 days after PTCAAs given in this study (human).
Source sentences
Summary
Lanreotide treatment resulted in minor reductions (P < .05) in free and total IGF-II and IGFBP-3, whereas insulin was unaltered.
3 context sentences(design, population, supporting numbers)
Summary · context
We measured fasting serum total (extractable) IGF-I in 553 patients in a controlled clinical trial.
Summary · context
Half of the patients received continuous subcutaneous infusion of the somatostatin analogue lanreotide from the day before (baseline) and for 4 days after PTCA.
Summary · context
We also measured ultrafiltrated serum free IGF-I and IGF-II, total IGF-II, IGF-binding protein-1 (IGFBP-1), IGFBP-3, and insulin in a subgroup of 18 placebo-treated and 20 lanreotide-treated patients.
Report a problemFND-0892178906
07HumanNon-randomized trialEfficacy outcome
In PTCA patients, insulin was unaltered with lanreotide treatment.
In plain wordsIn patients undergoing PTCA, insulin did not change with lanreotide.
Peptide
Lanreotide
Outcome
No significant changeInsulin
Study
n = 20
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · continuous subcutaneous infusion · from the day before PTCA through 4 days after PTCAAs given in this study (human).
Source sentences
Summary
Lanreotide treatment resulted in minor reductions (P < .05) in free and total IGF-II and IGFBP-3, whereas insulin was unaltered.
3 context sentences(design, population, supporting numbers)
Summary · context
We measured fasting serum total (extractable) IGF-I in 553 patients in a controlled clinical trial.
Summary · context
Half of the patients received continuous subcutaneous infusion of the somatostatin analogue lanreotide from the day before (baseline) and for 4 days after PTCA.
Summary · context
We also measured ultrafiltrated serum free IGF-I and IGF-II, total IGF-II, IGF-binding protein-1 (IGFBP-1), IGFBP-3, and insulin in a subgroup of 18 placebo-treated and 20 lanreotide-treated patients.
Report a problemFND-0892178907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.